NSE: CAPLIPOINT | BSE: 524742

Mid-range Performer

Download real time

2135.20 -21.70 (-1.01%)

High vol.+gain this week

NSE 14 Aug, 2025 3:45 PM (IST)

16,230

Market Cap

High in industry

1.4

Beta 1Year

Very High Volatility

Dividend

Caplin Point Laboratories Ltd. has an upcoming dividend of ₹3.00 per share due on 12 Sep 2025 See details

Caplin Point Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CAPLIPOINT, BSE:524742 Caplin Point Laboratories Ltd.

Caplin Point Laboratories Ltd.

03 Nov 2021

2135.20

-1.01%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Securities Limited

For LatAm markets, it outsources ~40% of products from China, ~20% from Indian vendors and in-house manufacturing of the remaining ~40% Caplin Steriles caters to the rapidly growing demand for injectable products in US and other regulated markets...

Caplin Point Laboratories Ltd. has gained 35.81% in the last 1 Year

Caplin Point Laboratories Ltd.

07 May 2021

2135.20

-1.01%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Securities Limited

Q4FY21 revenues grew 29.5% YoY to | 279 crore. EBITDA margins improved 575 bps YoY to 30.7% due to lower gross margins in the base year due to certain one-offs. Subsequently, EBITDA grew 59.3% YoY to | 86 crore. PAT grew 35.8% YoY to | 66 crore due to lower other income. On a...

Caplin Point Laboratories Ltd. is trading above all available SMAs

Caplin Point Laboratories Ltd.

05 Feb 2021

2135.20

-1.01%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

ICICI Securities Limited

The Q3FY21 operational performance was mostly in line with our expectations whereas profitability was below due to lower than expected other income. Revenues grew 20.2% YoY to | 274 crore. EBITDA margins improved 89 bps YoY to 30.6% due to higher gross margins, lower other expenses partly offset by higher staff costs likely due to acquired subsidiaries. Hence, EBITDA grew 23.9% YoY to | 84 crore. However, PAT...

Caplin Point Laboratories Ltd. is trading above all available SMAs

Caplin Point Laboratories Ltd.

30 Jan 2021

2135.20

-1.01%

CAPLIN POINT LABORATORIES LTD.

Buy: Caplin Point Laboratories ...

Ventura

Caplin Point Laboratories Ltd (CPLL) has a dominant presence in semi-regulated generic markets of Latin America (LatAm) and Africa. It forayed into these geographies in the 2000s and established a strong and deep network and monetized the early mover advantage in the then untapped markets.

Caplin Point Laboratories Ltd. has gained 10.66% in the last 1 Week

Caplin Point Laboratories Ltd.

06 Nov 2020

2135.20

-1.01%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Securities Limited

Emerging markets (EM) account for 92% of revenues and consist of LatAm - 87% (both Central, South America) and Africa- 5%. Revenues grew at 25% CAGR over a decade mainly due to 1) early mover advantage in these untapped markets, 2) geographical expansion (starting with two countries to 10 currently), 3) ability to address market gaps, especially in generics space (via trading model) with a hold on end-to-end distribution channels. We expect growth momentum to persist mainly due to further expansion in front end, increasing product basket, change in product mix, launching of own...

Caplin Point Laboratories Ltd. high volume past week with price gain of 10.66.

Caplin Point Laboratories Ltd.

17 Aug 2020

2135.20

-1.01%

CAPLIN POINT LABORATORIES LTD.

Buy: Caplin Point Laboratories ...

Ventura

Quick Research Note

Caplin Point Laboratories Ltd. high volume past week with price gain of 10.66.

Caplin Point Laboratories Ltd.

12 Aug 2020

2135.20

-1.01%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Securities Limited

Q1FY21 revenues grew a robust 24.7% YoY to | 240.1 crore. EBITDA margins fell 517 bps YoY to 29.8% due to higher operational costs. Sequential margin improvement (up 483 bps) was on account of better gross margins (one-off impact in Q4FY20) despite higher staff costs due to recently acquired subsidiaries. Subsequently, EBITDA grew 6.3% YoY, 33.1% QoQ to | 71.6 crore. PAT grew 8.6% YoY to | 54.5 crore. Delta vis-a-vis EBITDA...